Merrimack Pharmaceuticals, Inc. – NASDAQ:MACK

Add to watchlist

Market closed

Open in about 15 hours

+2.92%

month

+8.15%

quarter

+18.02%

year

Market Cap	223.97M
Enterprise value	N/A

P/E	-8.91
EV/Sales	N/A
EV/EBITDA	4.51
Price/Sales	N/A
Price/Book	0.98
PEG ratio	0.27
EPS	-1.70

Revenue	N/A
EBITDA	-2.25M
Income	-24.54M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Profit Margin

Q Y

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Profit margin
Jun 2023	0	-391K
Sep 2023	0	-279K
Dec 2023	0	-240K
Mar 2024	0	-23.63M

MACK income statement history

Dividends

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Payout ratio
Payout ratio	0%

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Dividend Yield
2019	63.48%
2020
2021
2022
2023

MACK dividends history

Debt to Assets

Q Y

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Debt to assets
Jun 2023	19448000	411K	2.11%
Sep 2023	19299000	493K	2.55%
Dec 2023	19188000	441K	2.3%
Mar 2024	244322000	22.67M	9.28%

MACK balance sheet history

Cash Flow

Q Y

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Cash Flow
Jun 2023	-668K	-8.81M	209K
Sep 2023	-203K	-3.84M	0
Dec 2023	-295K	68K	133K
Mar 2024	-1.31M	228M	1.48M

MACK cash flow history

Merrimack Pharmaceuticals
Hedge Funds Holdings Q1 2023

16.56% -39.77%

of MACK is owned by hedge funds

29 -17

hedge funds hold MACK stock

2.24M -5.31M

shares is hold by hedge funds

MACK hedge funds holdings changes

Merrimack Pharmaceuticals
Insider Trading

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Insider trades (number of shares)
Period	Buy	Sel
Jan 2023	189353	0
Mar 2023	160590	0
Aug 2023	225550	0
Nov 2023	74268	0
Dec 2023	150600	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	28 Dec 2023	ANDERSEN ERIC director	Common Stock	857	$13.35	$11,441
Purchase	26 Dec 2023	ANDERSEN ERIC director	Common Stock	48,693	$13.15	$640,313
Purchase	7 Dec 2023	ANDERSEN ERIC director	Common Stock	76,384	$12.85	$981,534
Purchase	7 Dec 2023	ANDERSEN ERIC director	Common Stock	24,666	$12.85	$316,958
Purchase	17 Nov 2023	ANDERSEN ERIC director	Common Stock	235	$12.5	$2,938
Purchase	17 Nov 2023	ANDERSEN ERIC director	Common Stock	65	$12.5	$813
Purchase	14 Nov 2023	ANDERSEN ERIC director	Common Stock	39,283	$12.5	$491,038
Purchase	14 Nov 2023	ANDERSEN ERIC director	Common Stock	10,887	$12.5	$136,088
Purchase	9 Nov 2023	ANDERSEN ERIC director	Common Stock	7,810	$12.19	$95,220
Purchase	9 Nov 2023	ANDERSEN ERIC director	Common Stock	2,165	$12.19	$26,396

MACK insider trading transactions

Merrimack Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application ANTI-TNFR2 ANTIBODIES AND USES THEREOF Filling date: 28 Feb 2020 Issue date: 8 Sep 2022	28 Feb 2020	8 Sep 2022
Application	Application ANTI-TNFR2 ANTIBODIES AND USES THEREOF Filling date: 18 Sep 2019 Issue date: 2 Dec 2021	18 Sep 2019	2 Dec 2021
Application	Application Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics Filling date: 16 Mar 2017 Issue date: 3 Oct 2019	16 Mar 2017	3 Oct 2019
Application	Application ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF Filling date: 5 Nov 2018 Issue date: 26 Sep 2019	5 Nov 2018	26 Sep 2019

MACK patents

Merrimack Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q3 2018 7 Nov 2018	Q3 2018 Earnings Call Transcript
Q2 2018 7 Aug 2018	Q2 2018 Earnings Call Transcript
Q1 2018 8 May 2018	Q1 2018 Earnings Call Transcript
Q4 2017 12 Mar 2018	Q4 2017 Earnings Call Transcript

MACK earnings call transcripts

Merrimack Pharmaceuticals
Executives

Insider	Age	Since	Compensation
Dr. Ulrik B. Nielsen (1972) Co-Founder & Independent Director	53		$76,880
Mr. Gary L. Crocker M.B.A., MBA (1952) Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, Chief Executive Officer & Chairman	73		$74,500

Merrimack Pharmaceuticals
Latest News

Friday, 10 May 2024
16:30	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	businesswire.com
Tuesday, 30 April 2024
17:15	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	businesswire.com
Wednesday, 27 March 2024
16:30	Merrimack Receives $225 Million Milestone Payment from Ipsen	businesswire.com
Thursday, 7 March 2024
16:30	Merrimack Reports Full Year 2023 Financial Results	businesswire.com
Tuesday, 13 February 2024
16:18	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	businesswire.com
Wednesday, 4 January 2023
10:33	Merrimack Still Has Significant Arbitrage Potential	Seeking Alpha
Wednesday, 9 November 2022
13:12	Merrimack Pharmaceuticals (MACK) Stock Skyrockets Over 240%: Details	Pulse2
10:13	Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment	Market Watch
Monday, 31 October 2022
09:00	Return Of The Mack: A Deeply Misunderstood Near-Term Readout	Seeking Alpha

Ideas & Opinions

Seeking Alpha 4 Jan 2023

Merrimack Still Has Significant Arbitrage Potential
Seeking Alpha 31 Oct 2022

Return Of The Mack: A Deeply Misunderstood Near-Term Readout

Frequently Asked Questions (FAQ)

When is Merrimack Pharmaceuticals's next earnings date?

Unfortunately, Merrimack Pharmaceuticals's (MACK) next earnings date is currently unknown.
Does Merrimack Pharmaceuticals pay dividends?

Yes, Merrimack Pharmaceuticals pays dividends and its trailing 12-month yield is 199.41% with 0% payout ratio. The last Merrimack Pharmaceuticals stock dividend of $0.5 was paid on 23 Dec 2019.
How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals has a market capitalization of 223.97M.
What is Merrimack Pharmaceuticals's stock symbol?

Merrimack Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "MACK".
What is Merrimack Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Merrimack Pharmaceuticals?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Merrimack Pharmaceuticals's key executives?
Merrimack Pharmaceuticals's management team includes the following people:
- Dr. Ulrik B. Nielsen Co-Founder & Independent Director(age: 53, pay: $76,880)
- Mr. Gary L. Crocker M.B.A., MBA Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, Chief Executive Officer & Chairman(age: 73, pay: $74,500)
Is Merrimack Pharmaceuticals founder-led company?

Yes, Merrimack Pharmaceuticals is a company led by its founder Dr. Ulrik B. Nielsen.
When Merrimack Pharmaceuticals went public?

Merrimack Pharmaceuticals, Inc. is publicly traded company for more then 13 years since IPO on 29 Mar 2012.
What is Merrimack Pharmaceuticals's official website?

The official website for Merrimack Pharmaceuticals is merrimack.com.
Where are Merrimack Pharmaceuticals's headquarters?

Merrimack Pharmaceuticals is headquartered at One Broadway, Cambridge, MA.
How can i contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals's mailing address is One Broadway, Cambridge, MA and company can be reached via phone at +61 77208606.

Merrimack Pharmaceuticals, Inc.

merrimack.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

+61 77208606

One Broadway
Cambridge, MA 02142

CIK: 0001274792
ISIN: US5903282094
CUSIP: 590328209